source
- Novartis' del-desiran misses primary goal in late-stage myotonic dystrophy trialNovartis announced that its experimental RNA drug del-desiran did not achieve the primary endpoint in a late-stage study of myotonic dystrophy type 1, a rare muscle‑weakening disease. The trial me…
- Novartis and Ionis's pelacarsen fails to cut heart events despite lowering Lp(a) levelsNovartis and Ionis reported that pelacarsen, an RNA therapy aimed at lowering lipoprotein(a), did not reduce major cardiovascular events in a Phase 3 trial of over 8,000 patients. The study compare…